Translational Research

Inflammatory bowel disease (IBD) translational research is directed by Dermot McGovern, MD.  Dr. McGovern is a gastroenterologist with a doctorate in molecular and population genetics.  He uses his talents to accelerate the pace of translational work and streamline and perfect study design and data analysis.

Firmly entrenched in Cedars-Sinai's “bench to bedside and back to bench” philosophy, the F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute uses translational research to analyze the results of clinical investigations for important insights into new basic research avenues. Due to Cedars-Sinai's emphasis on inflammatory bowel disease, the clinical program and participation in both clinical and basic research, physician/scientists at the Institute are in a position to make clinical observations that can be immediately investigated and applied towards changes and improvements in patient care.  This leads to a “personalized medicine” approach to treating our patients.

Translational research studies underway include:

  • Investigating the role of genetic variation and clinical factors in predicting the need for colectomy in medically-refractive ulcerative colitis
  • Investigation of the genetic and clinical factors predicting osteoporosis in IBD patients
  • Study of genetic, serological and clinical factors predicting disease recurrence following surgical resection in Crohn's disease
  • Investigation of the pharmacogenetics of anti-TNF therapy, thiopurine therapy and methotrexate in IBD
  • Phenotype/genotype associations in both ulcerative colitis and Crohn's disease
  • Identification of IBD susceptibility loci in a number of ethnic groups including Hispanics, Ashkenazi Jewish, African-Americans and Asians
  • Epidemiological studies of the extra-intestinal manifestations of IBD and the role of mucosal inflammation in the spondyloarthropathies
  • Gene-environmental interaction with a particular emphasis on smoking and host-microbial interaction
  • Genotypes and biologic phenotypes of ulcerative colitis and Crohn's disease